Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Olivia Feehan-Nelson"'
Autor:
Marielle E. Yohe, Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, Stacey Stauffer, Olivia Feehan-Nelson, Wenyue Sun, Kristine A. Isanogle, Christina M. Robinson, Amy James, Parirokh Awasthi, Priya Shankarappa, Xiaoling Liu, Haiyan Lei, Donna Butcher, Roberta Smith, Elijah F. Edmonson, Jin-Qui Chen, Noemi Kedei, Cody S. Peer, Jack F. Shern, W. Douglas Figg, Lu Chen, Matthew D. Hall, Simone Difillipantonio, Frederic G. Barr, Robert L. Kortum, Angelina V. Vaseva, Javed Khan
Publikováno v:
Clinical Cancer Research. 28:IA023-IA023
Background: PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7890151a1334855c892ebb63b178b742
https://doi.org/10.1158/1557-3265.sarcomas22-ia023
https://doi.org/10.1158/1557-3265.sarcomas22-ia023
Autor:
Katie E. Hebron, Olivia Feehan-Nelson, Angela Kim, Xiaoying Jian, Sofia A Girald, Paul Randazzo, Marielle E. Yohe
Publikováno v:
Clinical Cancer Research. 28:A003-A003
Despite aggressive, multimodal therapies, the prognosis of patients with refractory or recurrent rhabdomyosarcoma (RMS) has not improved in four decades. RMS is thought to arise due to defective differentiation in skeletal muscle precursor cells. Dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd4c048b016ee0c80a2b48752444279a
https://doi.org/10.1158/1557-3265.sarcomas22-a003
https://doi.org/10.1158/1557-3265.sarcomas22-a003